Prof. Guoxiang Cai 蔡国响
Chief Physician, Professor
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and multidisciplinary treatment of colorectal and abdominal tumors, including laparoscopic surgery, ultra-low sphincter-preserving rectal cancer surgery, and management of liver and peritoneal metastases.
Dr. Cai holds a PhD in Oncology from Fudan University and completed postdoctoral training at Johns Hopkins Medicine. As Chief Physician and Deputy Director of General Surgery at Fudan University Shanghai Cancer Center, Dr. Cai leads research on colorectal cancer recurrence and peritoneal metastases, securing multiple national grants and publishing 66 SCI papers.
Professional roles
- Vice Chair, Youth Committee of Colorectal Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Youth Committee of Oncology Branch, Chinese Medical Association
- Standing Committee Member, Peritoneal Tumor Professional Committee, China Anti-Cancer Association
- Editorial Board Member, International Journal of Oncology
Name order: in Chinese the family name comes first (Cai Guoxiang). Papers usually list the name as Guoxiang Cai or Cai G.
Selected publications
127 papers on PubMed matched by name and affiliation; 45 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancers (Basel), 2025 (senior author): Correction: Han et al. Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer. Cancers 2023, 15, 562. PubMed 41463286
- J Hematol Oncol, 2025 (senior author): Correction: myCAF-derived Exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment. PubMed 40102959
- Nat Cancer, 2025 (senior author): Microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells promotes peritoneal metastasis of colorectal cancer. PubMed 39966610
- J Hematol Oncol, 2024 (senior author): myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment. PubMed 39696364
- Clin Transl Med, 2024 (senior author): A comprehensive overview of the molecular features and therapeutic targets in BRAF(V600E)-mutant colorectal cancer. PubMed 39073010
- JAMA Oncol, 2023 (senior author): Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. PubMed 37079312
- Cancers (Basel), 2023 (senior author): Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer. PubMed 36765520
- EClinicalMedicine, 2023 (senior author): Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: A multicentre cohort study. PubMed 36386039
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion